Maxim Maintains Buy On StemCells Following Pathway Phase II Update
In a research report sent to investors today, Maxim’s healthcare analyst Jason Kolbert maintained a Buy rating on StemCells (NASDAQ:STEM) with a $5 price target, as the company announced that the first patient in the phase II ‘Pathway’ study in cervical spinal cord injury was transplanted with its proprietary HuCNS-SCs.
Kolbert observed, “The study, titled “Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury”, is the first clinical trial designed to evaluate both the safety and efficacy of transplanting human neural stem cells into patients with cervical spinal cord injury. Traumatic injuries to the cervical region of the spinal cord (tetraplegia or quadriplegia, partial or total loss of use of all limbs). Patients that are transplanted with HuCNS-SCs will be monitored for one year to assess chances of motor function according to ISNCSCI. The primary endpoints will assess changes in patient upper extremity strength as measured in the hands, arms and shoulders. The trial will enroll up to 52 patients.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 4.1% and a 41.2% success rate. Kolbert has a -31.7% average return when recommending STEM, and is ranked #860 out of 3423 analysts.